Which peptides are studied in relation to the blood-brain barrier?
A research-supply overview of the peptides, proteins and peptide-directed delivery systems studied in relation to blood-brain barrier permeability, transport and retention, with the model systems and populations each fin
The blood-brain barrier (BBB) is the specialised interface formed by brain endothelial cells, their tight junctions, pericytes, astrocyte end-feet and the surrounding neurovascular unit. In the research literature, the term covers both a physical diffusion barrier and an active transport system, and the compounds studied against it fall into two broad classes: endogenous signalling peptides and proteins that are measured as markers of barrier state, and engineered peptide- or antibody-based shuttles designed to cross or bypass the barrier. Identifiers such as sequence, molecular formula and molecular weight are compound-specific and are not supplied in the evidence summarised here; where a study reports a named protein, the name is given as it appears in that source.
Work in this area centres on receptor-mediated transcytosis (RMT) at the barrier, particularly transferrin receptor (TfR)-mediated shuttle systems, together with the insulin-like growth factor 1 receptor and intra-brain protein targets used to extend retention after entry [4].
Research Studies
Cerebrolysin and blood-brain barrier injury after extended-window thrombectomy
A multicentre randomised clinical trial is evaluating whether Cerebrolysin, administered after successful extended-window endovascular thrombectomy, reduces brain tissue injury and supports recovery [3]. The rationale given is that ongoing injury to brain tissue, small vessels and the blood-brain barrier may contribute to incomplete recovery in patients whose blocked artery has been reopened. The trial enrols patients treated 6 to 24 hours after stroke onset, a population in which thrombectomy can benefit selected cases but in which some patients remain disabled despite successful reperfusion [3].
Transcutaneous auricular vagal nerve stimulation and radiation necrosis-related cerebral edema
A multi-centre, randomised, blinded trial is assessing transcutaneous auricular vagal nerve stimulation (taVNS) in radiation necrosis-related cerebral edema [1]. Participants are assigned to a treatment arm or a sham arm, and both arms undergo imaging plus tissue and blood collection. The endpoints include change in area of contrast enhancement and cerebral edema, inflammatory markers, and markers of blood-brain barrier permeability [1]. This is a clinical study in patients with radiation necrosis, not a peptide administration study; it is included because BBB permeability is a measured outcome.
Dual-targeted antibodies and sustained brain retention
Antibody delivery to the brain has increasingly been pursued through RMT approaches such as TfR-mediated shuttle systems, and a newer strategy targets intra-brain proteins to slow clearance of TfR shuttles from the brain [4]. The proposed approach combines binding to intra-brain proteins — myelin oligodendrocyte glycoprotein (MOG), cell adhesion molecule 3, and chondroitin sulfate proteoglycan 5 — with binding to BBB proteins including TfR and the insulin-like growth factor 1 receptor [4]. The stated aim is efficient brain delivery together with sustained retention [4].
Circulating placental growth factor and barrier disruption in glioblastoma
In glioblastoma, angiogenesis is multifactorial and blood-brain barrier disruption permits detection of circulating mediators [6]. A prospective observational study examined circulating placental growth factor (PlGF) in 54 patients with IDH-wildtype glioblastoma, analysing plasma samples collected at diagnosis and at recurrence with a multiplex panel of angiogenesis mediators, and testing associations with clinical, radiological, molecular and treatment-related variables [6]. The population is high-risk glioblastoma patients; the measurement is a circulating protein, not an administered peptide.
Ketamine, astrocyte mitochondria and adenosine, humanin and melatonin efflux
A review of the ketamine literature reports that antidepressant efficacy has classically been attributed to noncompetitive antagonism of the N-methyl-D-aspartate receptor (NMDAR) on the neuronal postsynaptic membrane, reducing excessive Ca²⁺ influx through the NMDAR channel [5]. The same review describes low-dose ketamine as preconditioning astrocyte mitochondria, with efficacy linked to upregulation and efflux of adenosine, humanin and melatonin [5]. Humanin is a peptide, and its appearance here is as an endogenous effector in a proposed astrocyte-centred mechanism rather than as an exogenous BBB-crossing agent.
Senescent brain endothelial cells and nanoparticle-delivered senolytics
Brain endothelial cell senescence is described as a key factor in blood-brain barrier impairment during physiological aging, with potential downstream cognitive decline and neurodegenerative disease onset [8]. In this work, polymeric nanoparticles loaded with the senolytic agent Navitoclax were designed to selectively eliminate senescent cells; the particles are taken up by both proliferative and senescent brain endothelial cells but are degraded only in the latter, where senescence-associated beta-galactosidase (SA-β-gal) is present, releasing the drug to induce cell death [8]. The model is aged brain endothelium, and the delivered agent is a small-molecule senolytic rather than a peptide.
Circadian clock pathways and barrier-relevant neurodegeneration
A narrative review synthesises literature on circadian dysfunction in Alzheimer's disease, covering biomarker profiles and treatment response [7]. Mechanistic studies cited in that review suggest interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity and proteostasis, with circadian-regulated pathways including BMAL1-SIRT1 and NF-κB-NLRP signalling implicated [7]. This is a review of Alzheimer's disease biology; it does not report a peptide crossing the barrier.
Protein-energy wasting in chronic kidney disease and anabolic resistance
Protein-energy wasting drives morbidity and mortality in advanced chronic kidney disease, and a subset of uremic patients may show a defining nutritional paradox in which standard nutritional interventions — oral supplements and intradialytic parenteral nutrition — are often insufficient [2]. The proposed explanation is systemic anabolic resistance, distinct from simple starvation, which responds to caloric and protein supplementation [2]. The population is advanced CKD patients; the relevance to barrier research is indirect and the source does not report a BBB transport measurement.
Comparison of model systems and measured endpoints
| Study focus | Population or model | Barrier-related endpoint |
|---|---|---|
| Cerebrolysin after thrombectomy [3] | Patients treated 6–24 h after stroke onset | Brain tissue injury and recovery after reperfusion |
| taVNS for radiation necrosis [1] | Patients with radiation necrosis-related cerebral edema | Markers of BBB permeability; contrast enhancement and edema area |
| Dual-targeted antibody shuttle [4] | Preclinical delivery approach | RMT via TfR and IGF1R; retention via MOG, CADM3, CSPG5 |
| Circulating PlGF in GBM [6] | 54 patients with IDH-wildtype glioblastoma | Plasma angiogenesis mediators at diagnosis and recurrence |
| Senolytic nanoparticles [8] | Aged brain endothelial cells | Selective elimination of senescent BECs |
If you are reading this for personal health reasons
The materials described on this page are supplied for laboratory research use only, and nothing here is intended for human consumption. We do not provide dosing information, treatment protocols or medical guidance of any kind. Anyone considering a compound for their own use should speak to a licensed clinician.
Sources
- [1] TENS of Auricular Vagal Nerve for Radiation Necrosis — ClinicalTrials.gov
- [2] Perspectives on the Nutritional Paradox in Uremia: A "Sensitize-Then-Feed" Framework for Protein-Energy Wasting — Europe PMC
- [3] Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy — ClinicalTrials.gov
- [4] Efficient brain delivery and sustained retention of antibodies via dual targeting of blood-brain barrier and intra-brain proteins — Europe PMC
- [5] Low Dose Ketamine Preconditions Astrocyte Mitochondria to Achieve Antidepressant Efficacy via Adenosine, Humanin, and Melatonin Upregulation and Efflux — Europe PMC
- [6] Circulating Placental Growth Factor as a Prognostic Biomarker in High-Risk Glioblastoma Patients — Europe PMC
- [7] Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications — Europe PMC
- [8] Nanoparticles as an efficient strategy to eliminate senescent brain endothelial cells — Europe PMC
- [9] Fragment morphometry analysis and same-color-channel separation enable reproducible quantification across BBB models — Europe PMC
- [10] Elevated acute-phase plasma SPARC levels precede the development of angiographic vasospasm and delayed cerebral ischemia in severe aneurysmal subarachnoid hemorrhage — Europe PMC
- [11] Herbal nanoparticles in the treatment of neurodegeneration: from molecular mechanisms to therapeutic translation — Europe PMC
- [12] Neuroimmune interactions: from molecular mechanisms to therapeutic targets — Europe PMC